Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21118915rdf:typepubmed:Citationlld:pubmed
pubmed-article:21118915lifeskim:mentionsumls-concept:C0279516lld:lifeskim
pubmed-article:21118915lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:21118915lifeskim:mentionsumls-concept:C1136254lld:lifeskim
pubmed-article:21118915lifeskim:mentionsumls-concept:C0037633lld:lifeskim
pubmed-article:21118915lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:21118915lifeskim:mentionsumls-concept:C1382100lld:lifeskim
pubmed-article:21118915lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:21118915lifeskim:mentionsumls-concept:C0450254lld:lifeskim
pubmed-article:21118915lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:21118915pubmed:issue2lld:pubmed
pubmed-article:21118915pubmed:dateCreated2011-3-11lld:pubmed
pubmed-article:21118915pubmed:abstractTextE-101 Solution (E-101) is a novel myeloperoxidase-mediated antimicrobial. It is composed of porcine myeloperoxidase (pMPO), glucose oxidase, glucose as the substrate and specific amino acids in an aqueous vehicle. E-101 is being developed for topical application directly into surgical wounds to prevent surgical site infections (SSIs). The in vitro activity of E-101 was investigated.lld:pubmed
pubmed-article:21118915pubmed:languageenglld:pubmed
pubmed-article:21118915pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21118915pubmed:citationSubsetIMlld:pubmed
pubmed-article:21118915pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21118915pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21118915pubmed:statusMEDLINElld:pubmed
pubmed-article:21118915pubmed:monthFeblld:pubmed
pubmed-article:21118915pubmed:issn1460-2091lld:pubmed
pubmed-article:21118915pubmed:authorpubmed-author:DenysGerald...lld:pubmed
pubmed-article:21118915pubmed:authorpubmed-author:O'HanleyPeter...lld:pubmed
pubmed-article:21118915pubmed:authorpubmed-author:GroverParveen...lld:pubmed
pubmed-article:21118915pubmed:authorpubmed-author:StephensJacks...lld:pubmed
pubmed-article:21118915pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21118915pubmed:volume66lld:pubmed
pubmed-article:21118915pubmed:ownerNLMlld:pubmed
pubmed-article:21118915pubmed:authorsCompleteYlld:pubmed
pubmed-article:21118915pubmed:pagination335-42lld:pubmed
pubmed-article:21118915pubmed:meshHeadingpubmed-meshheading:21118915...lld:pubmed
pubmed-article:21118915pubmed:meshHeadingpubmed-meshheading:21118915...lld:pubmed
pubmed-article:21118915pubmed:meshHeadingpubmed-meshheading:21118915...lld:pubmed
pubmed-article:21118915pubmed:meshHeadingpubmed-meshheading:21118915...lld:pubmed
pubmed-article:21118915pubmed:meshHeadingpubmed-meshheading:21118915...lld:pubmed
pubmed-article:21118915pubmed:meshHeadingpubmed-meshheading:21118915...lld:pubmed
pubmed-article:21118915pubmed:year2011lld:pubmed
pubmed-article:21118915pubmed:articleTitleIn vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens.lld:pubmed
pubmed-article:21118915pubmed:affiliationClarian Pathology Laboratory, Indianapolis, IN 46202, USA.lld:pubmed
pubmed-article:21118915pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21118915pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed